The full-length article titled; “Oncology KOLS: An Important Piece of the Puzzle” can be found online at: https://www.pharmavoice.com/article/2015-09-oncology-kol/ and the magazine edition can be viewed at: https://viewer.zmags.com/publication/d55281bd#/d55281bd/38.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, “We are relying heavily on the advice of our three world-renowned physicians in oncology in designing of our upcoming clinical trial in patients with advanced pancreatic cancer and in a separate trial we are in the process of planning. Working collaboratively, their input has allowed us to develop a strategy to address a clear unmet medical need for this dreadful disease and has helped us avoid pitfalls that otherwise might have occurred.”
PharmaCyte Biotech Chief Operating Officer, Dr. Gerald W. Crabtree, Ph.D., said, “We involve ‘thought leaders’ in both the oncology and diabetes arenas for our clinical development programs. Their advice is invaluable in helping us steer our treatment development programs in the right direction. The opportunity to be interviewed for this article and to speak on this topic allows us to share the benefits of bringing a team of thought leaders together in hopes that it can occur more frequently in the name of advancing disease treatments.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its related symptoms, as well as diabetes are being developed.
PharmaCyte Biotech’s treatment for pancreatic cancer involves encapsulating genetically modified human cells that convert the prodrug ifosfamide into its active or “cancer-killing” form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one-third the normal dose to eliminate the side effects normally associated with chemotherapy. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of ifosfamide takes place at or near the tumor. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
PharmaCyte Biotech is also developing treatments for cancer based upon the encapsulation of chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of the Cell-in-a-Box® technology in optimizing the anticancer effectiveness of Cannabis, while at the same time minimizing or outright eliminating the debilitating side effects often associated with cancer treatments.
In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation of the insulin producing live cells will be done using the Cell-in-a-Box® technology.
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations: PharmaCyte Biotech, Inc. Investor Relations Department Telephone: 917.595.2856 Email: Info@PharmaCyte.com
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | firstname.lastname@example.org